Phase 3 OCEANIC-STROKE trial shows asundexian cut recurrent ischemic stroke
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
Non-Cardioembolic Ischemic Stroke
DiseaseRelated News
Factor XIa Inhibitor Reduces Stroke Recurrence Without Increasing Bleeding Risk in Phase 3 Trial
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.